Relmada Therapeutics Inc
Change company Symbol lookup
Select an option...
RLMD Relmada Therapeutics Inc
LMND Lemonade Inc
NAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025
CG Carlyle Group Inc
ETR Entergy Corp
SKIN Beauty Health Co
PYR Pyrogenesis Canada Inc
KHZM Madison Ave Media Inc
PEO Adams Natural Resources Fund
MF Missfresh Ltd

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).

Closing Price
Day's Change
1.45 (4.56%)
B/A Size
Day's High
Day's Low

10-day average volume:

Ayr Wellness posts narrower loss as revenue nearly doubles

8:52 am ET May 26, 2022 (MarketWatch)

Ayr Wellness Inc. said Thursday its first-quarter loss narrowed to $7.58 million, or 11 cents a share, from $16.62 million, or 38 cents a share in the year-ago quarter. First-quarter revenue at the Miami-based cannabis company rose to $111.23 million from $58.4 million. Adjusted Ebitda increased to $19.5 million from $18.4 million. Analysts expected Ayr to lose 27 cents a share on revenue of $111.5 million, according to a FactSet survey. Looking ahead, Ayr said it's poised to benefit from the start of adult use sales in New Jersey and a new store in Boston starting in June. Shares of Ayr Wellness fell 1.9% in premarket trades. The stock is down by 58.7% thus far in 2022, compared to a loss of 45% by the AdvisorShares Pure US Cannabis ETF (MSOS).

-Steve Gelsi


(END) Dow Jones Newswires

May 26, 2022 08:52 ET (12:52 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.